Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MYC | P01106 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8908414 | 0.80 | GAA (0.36) | GAACA12CA1CA9TP53 | |
| SCHEMBL6887707 | 0.78 | CA12 (0.48) | GAACA12CA1CA9TP53 | |
| SCHEMBL317703 | 0.76 | KEAP1 (0.43) | GAACA12CA1CA9TP53 | |
| SCHEMBL31653832 | 0.76 | KEAP1 (0.43) | GAACA12CA1CA9TP53 | |
| SCHEMBL317626 | 0.76 | CA12 (0.42) | GAACA12CA1CA9TP53 | |
| SCHEMBL610788 | 0.75 | CA12 (0.41) | GAACA12CA1CA9TP53 | |
| SCHEMBL1464604 | 0.75 | CA12 (0.41) | GAACA12CA1CA9TP53 | |
| SCHEMBL10627311 | 0.74 | MCL1 (0.42) | GAACA12CA1CA9TP53 | |
| SCHEMBL27471377 | 0.74 | MYC (0.51) | GAATP53HPGDMYCKDM4E | |
| SCHEMBL9596295 | 0.73 | CA12 (0.39) | GAACA12CA1CA9TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3929202-A1 | MINIMAL SAPONIN ANALOGUES, SYNTHESIS AND USE THEREOF | Memorial Sloan-Kettering Cancer Center (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3149015-B1 | MINIMAL SAPONIN ANALOGUES, SYNTHESIS AND USE THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-07-21 | — | — | EP | disclosed |
| US-20210070796-A1 | MINIMAL SAPONIN ANALOGUES, SYNTHESIS AND USE THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2021-03-11 | — | — | US | disclosed |
| EP-2935335-B1 | NEW POLYPEPTIDES | AFFIBODY AB (SE) | 2020-10-28 | — | — | EP | disclosed |
| US-10626137-B2 | Minimal saponin analogues, synthesis and use thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2020-04-21 | — | — | US | disclosed |
| US-9957330-B2 | Polypeptides | AFFIBODY AB (SE) | 2018-05-01 | — | — | US | disclosed |
| US-20170096444-A1 | MINIMAL SAPONIN ANALOGUES, SYNTHESIS AND USE THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2017-04-06 | — | — | US | disclosed |
| EP-3149015-A1 | MINIMAL SAPONIN ANALOGUES, SYNTHESIS AND USE THEREOF | Memorial Sloan-Kettering Cancer Center (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20160289337-A1 | NEW POLYPEPTIDES | AFFIBODY AB (SE) | 2016-10-06 | — | — | US | disclosed |
| WO-2015184451-A1 | MINIMAL SAPONIN ANALOGUES, SYNTHESIS AND USE THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2015-12-03 | — | — | WO | disclosed |
| EP-2935335-A1 | NEW POLYPEPTIDES | Affibody AB (SE) | 2015-10-28 | — | — | EP | disclosed |
| US-9107965-B2 | Polypeptides | AFFIBODY AB (SE) | 2015-08-18 | — | — | US | disclosed |
| WO-2014096163-A1 | NEW POLYPEPTIDES | AFFIBODY AB (SE) | 2014-06-26 | — | — | WO | disclosed |
| US-8598113-B2 | Polypeptides | AFFIBODY AB (SE) | 2013-12-03 | — | — | US | disclosed |
| US-20130005653-A1 | POLYPEPTIDES | AFFIBODY AB (SE) | 2013-01-03 | — | — | US | disclosed |
| US-8247375-B2 | Polypeptides | AFFIBODY AB (SE) | 2012-08-21 | — | — | US | disclosed |
| US-20090016957-A1 | Polypeptides | AFFIBODY AB (SE) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096444-A1 | MINIMAL SAPONIN ANALOGUES, SYNTHESIS AND USE THEREOF | DDOST, SI, STT3A | GAA 134/4885CA12 291/4885CA1 1123/4885 |
| US-20210070796-A1 | MINIMAL SAPONIN ANALOGUES, SYNTHESIS AND USE THEREOF | DDOST, SI, STT3A | GAA 134/4885CA12 291/4885CA1 1123/4885 |
| US-10626137-B2 | Minimal saponin analogues, synthesis and use thereof | DDOST, SI, STT3A | GAA 134/4885CA12 291/4885CA1 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.